UBS Group
BTTX

UBS Group’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

UBS Group’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,954
Closed -$2.77K – 10011
2023
Q1 		$2.77K Buy
3,954
+3,749
+1,829% +$4.4K ﹤0.01% 8449
2022
Q4 		$228 Buy
+205
New +$302 ﹤0.01% 10296
2022
Q1 		– Sell
-2,969
Closed -$14K – 11148
2021
Q4 		$14K Buy
2,969
+636
+27% +$5.21K ﹤0.01% 8376
2021
Q3 		$23K Buy
2,333
+2,125
+1,022% +$21.1K ﹤0.01% 7031
2021
Q2 		$2K Buy
+208
New +$2.07K ﹤0.01% 9012

Other funds holding BTTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

UBS Group's BTTX Position: Q2 2023 in Review

UBS Group sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q2 2023, closing a stake of 3,954 shares — an estimated $2.77K sold.

UBS Group first reported a position in BTTX in Q2 2021 and held it in 5 quarters. The position peaked at $23K in Q3 2021. 15 funds tracked by Wall St. Rank hold BTTX as of Q2 2023.

  • UBS Group reported no remaining Better Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 3,954 Better Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.77K.
  • UBS Group first reported a position in Better Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • UBS Group's Better Therapeutics, Inc. Common Stock position peaked at $23K in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.